MBK Partners stands firm on its takeover offer which, as of April 30, had been accepted by 77.19% of AsiaPharmÆs shareholders. Templeton remains opposed to the deal.
Tag : asiapharm
The private equity company has no plans to raise its S$0.725 per share offer for the Chinese pharmaceutical firm, but reserves the right to revise the offer price if a competitive situation arises.
Templeton, a minority shareholder of AsiaPharm, is opposing a S$357.4 million management buyout offer for the Chinese pharmaceutical company and says the latest fourth quarter results are crucial in assessing the offer.